The antibacterial drug candidate known as SM1B74 was developed by researchers at NYU Grossman School of Medicine in New York City and Janssen Biotech. Researchers describe it as an “anti-S.aureus monoclonal antibody-centryin fusion protein” that works in part by dodging 10 of the pathogen’s disease-causing strategies, though without killing it — indicating a promising approach to address antibiotic resistance.
The drug candidate also reduced bacterial loads in the kidneys of infected mice when combined with small doses of the antibiotic vancomycin.
Read more here.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
